BMB Reports

Korean Society for Biochemistry and Molecular Biology (생화학분자생물학회)
권호 표지
DOI QR코드

DOI QR Code

Rapid functional screening of effective siRNAs against Plk1 and its growth inhibitory effects in laryngeal carcinoma cells

  • Lan, Huan (Department of Biochemistry and Molecular Biology, Chongqing Medical University) ;
  • Zhu, Jiang (Department of Otolaryngology, The First Affiliated Hospital, Chongqing Medical University) ;
  • Ai, Qing (Department of Biochemistry and Molecular Biology, Chongqing Medical University) ;
  • Yang, Zhengmei (Molecular Medicine and Cancer Research Center, Chongqing Medical University) ;
  • Ji, Ying (Department of Biochemistry and Molecular Biology, Chongqing Medical University) ;
  • Hong, Suling (Department of Otolaryngology, The First Affiliated Hospital, Chongqing Medical University) ;
  • Song, Fangzhou (Department of Biochemistry and Molecular Biology, Chongqing Medical University) ;
  • Bu, Youquan (Department of Biochemistry and Molecular Biology, Chongqing Medical University)
  • Received : 2010.10.25
  • Accepted : 2010.11.12
  • Published : 2010.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Plk 1 is overexpressed in many human malignancies including laryngeal carcinoma. However, its therapeutic potential has been never examined in laryngeal carcinoma. In the present study, a simple cellular morphology-based strategy was firstly proposed for rapidly screening the effective siRNAs against Plk1. Furthermore, we investigated the effects of Plk1 depletion via a novel identified effective siRNA against Plk1, Plk1 siRNA-607, on human laryngeal carcinoma Hep-2 cells. The results indicated that Plk1 siRNA-607 transfection resulted in a significant inhibition in Plk1 expression in cells, and subsequently caused a dramatic mitotic cell cycle arrest followed by massive apoptotic cell death, and eventually resulted in a significant decrease in growth and viability of the laryngeal carcinoma cells. Taken together, our present study not only suggests a simple strategy for rapidly screening effective siRNAs against Plk1 but also implicates that Plk1 may serve as a potential therapeutic target in human laryngeal carcinoma.

Keywords

References

  1. Glover, D. M., Hagan, I. M. and Tavares, A. A. (1998) Polo-like kinases: a team that plays throughout mitosis. Genes. Dev. 12, 3777-3787. https://doi.org/10.1101/gad.12.24.3777
  2. Golsteyn, R. M., Schultz, S. J., Bartek, J., Ziemiecki, A., Ried, T. and Nigg, E. A. (1994) Cell cycle analysis and chromosomal localization of human Plk1, a putative homologue of the mitotic kinases Drosophila polo and Saccharomyces cerevisiae Cdc5. J. Cell Sci. 107, 1509-1517.
  3. Strebhardt, K. and Ullrich, A. (2006) Targeting polo-like kinase 1 for cancer therapy. Nat. Rev. Cancer 6, 321-330. https://doi.org/10.1038/nrc1841
  4. Chopra, P., Sethi, G., Dastidar, S. G. and Ray, A. (2010) Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics. Expert. Opin. Investig. Drugs 19, 27-43. https://doi.org/10.1517/13543780903483191
  5. Degenhardt, Y. and Lampkin, T. (2010) Targeting Polo-like kinase in cancer therapy. Clin. Cancer Res. 16, 384-389. https://doi.org/10.1158/1078-0432.CCR-09-1380
  6. Takai, N., Hamanaka, R., Yoshimatsu, J. and Miyakawa, I. (2005) Polo-like kinases (Plks) and cancer. Oncogene. 24, 287-291. https://doi.org/10.1038/sj.onc.1208272
  7. Knecht, R., Elez R., Oechler, M., Solbach, C., von Ilberg, C. and Strebhardt, K. (1999) Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck. Cancer Res. 59, 2794-2797.
  8. Spankuch-Schmitt, B., Bereiter-Hahn, J., Kaufmann, M., and Strebhardt, K. (2002) Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. J. Natl. Cancer Inst. 94, 1863-1877. https://doi.org/10.1093/jnci/94.24.1863
  9. Rizki, A., Mott, J. D. and Bissell, M. J. (2007) Polo-like kinase 1 is involved in invasion through extracellular matrix. Cancer Res. 67, 11106-11110. https://doi.org/10.1158/0008-5472.CAN-07-2348
  10. Liu, X. and Erikson, R. L. (2003) Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc. Natl. Acad. Sci. U.S.A. 100, 5789-5794. https://doi.org/10.1073/pnas.1031523100
  11. Reagan-Shaw, S. and Ahmad, N. (2005) Silencing of polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer. FASEB J. 19, 611-613. https://doi.org/10.1096/fj.04-2910fje
  12. Liu, X., Lei, M. and Erikson, R. L. (2006) Normal cells, but not cancer cells, survive severe Plk1 depletion. Mol. Cell Biol. 26, 2093-2108. https://doi.org/10.1128/MCB.26.6.2093-2108.2006
  13. Bumcrot, D., Manoharan, M., Koteliansky, V. and Sah, D. W. (2006) RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat. Chem. Biol. 2, 711-719. https://doi.org/10.1038/nchembio839
  14. Tiemann, K. and Rossi, J. J. (2009) RNAi-based therapeutics-current status, challenges and prospects. EMBO Mol. Med. 1, 142-151. https://doi.org/10.1002/emmm.200900023
  15. Bu, Y., Yang, Z., Li, Q. and Song, F. (2008) Silencing of polo-like kinase (Plk) 1 via siRNA causes inhibition of growth and induction of apoptosis in human esophageal cancer cells. Oncology 74, 198-206. https://doi.org/10.1159/000151367
  16. Marioni, G., Marchese-Ragona, R., Cartei, G., Marchese, F. and Staffieri, A. (2006) Current opinion in diagnosis and treatment of laryngeal carcinoma. Cancer Treat. Rev. 32, 504-515. https://doi.org/10.1016/j.ctrv.2006.07.002
  17. Papadas, T. A., Alexopoulos, E. C., Mallis, A., Jelastopulu, E., Mastronikolis, N. S. and Goumas, P. (2010) Survival after laryngectomy: a review of 133 patients with laryngeal carcinoma. Eur. Arch. Otorhinolaryngol. 267, 1095-1101. https://doi.org/10.1007/s00405-009-1156-8
  18. Juan, G., Traganos, F., James, W. M., Ray, J. M., Roberge, M., Sauve, D. M., Anderson, H. and Darzynkiewicz, Z. (1998) Histone H3 phosphorylation and expression of cyclins A and B1 measured in individual cells during their progression through G2 and mitosis. Cytometry 32, 71-77. https://doi.org/10.1002/(SICI)1097-0320(19980601)32:2<71::AID-CYTO1>3.0.CO;2-H
  19. Tilesi, F., Fradiani, P., Socci, V., Willems, D. and Ascenzioni, F. (2009) Design and validation of siRNAs and shRNAs. Curr. Opin. Mol. Ther. 11, 156-164.
  20. Huesken, D., Lange, J., Mickanin, C., Weiler, J., Asselbergs, F., Warner, J., Meloon, B., Engel, S., Rosenberg, A., Cohen, D., Labow, M., Reinhardt, M., Natt, F. and Hall, J. (2005) Design of a genome-wide siRNA library using an artificial neural network. Nat. Biotechnol. 23, 995-1001. https://doi.org/10.1038/nbt1118
  21. Hung, C. F., Lu, K. C., Cheng, T. L., Wu, R. H., Huang, L. Y., Teng, C. F. and Chang, W. T. (2006) A novel siRNA validation system for functional screening and identification of effective RNAi probes in mammalian cells. Biochem. Biophys. Res. Commun. 346, 707-720. https://doi.org/10.1016/j.bbrc.2006.05.164
  22. Luo, Q., Kang, Q., Song, W. X., Luu, H. H., Luo, X., An, N., Luo, J., Deng, Z. L., Jiang, W., Yin, H., Chen, J., Sharff, K. A., Tang, N., Bennett, E., Haydon, R. C. and He, T. C. (2007) Selection and validation of optimal siRNA target sites for RNAi-mediated gene silencing. Gene 395, 160-169. https://doi.org/10.1016/j.gene.2007.02.030
  23. Liu, X. and Erikson, R. L. (2002) Activation of Cdc2/cyclin B and inhibition of centrosome amplification in cells depleted of Plk1 by siRNA. Proc. Natl. Acad. Sci. U.S.A. 99, 8672-8676. https://doi.org/10.1073/pnas.132269599
  24. Roshak, A. K., Capper, E. A., Imburgia, C., Fornwald, J., Scott, G. and Marshall, L. A. (2000) The human polo-like kinase, PLK, regulates cdc2/cyclin B through phosphorylation and activation of the cdc25C phosphatase. Cell Signal 12, 405-411. https://doi.org/10.1016/S0898-6568(00)00080-2
  25. Yamada, S., Ohira, M., Horie, H., Ando, K., Takayasu, H., Suzuki, Y., Sugano, S., Hirata, T., Goto, T., Matsunaga, T., Hiyama, E., Hayashi, Y., Ando, H., Suita, S., Kaneko, M., Sasaki, F., Hashizume, K., Ohnuma, N. and Nakagawara, A. (2004) Expression profiling and differential screening between hepatoblastomas and the corresponding normal livers: identification of high expression of the PLK1 oncogene as a poor-prognostic indicator of hepatoblastomas. Oncogene 23, 5901-5911. https://doi.org/10.1038/sj.onc.1207782
  26. Livak, K. J. and Schmittgen, T. D. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402-408. https://doi.org/10.1006/meth.2001.1262

Cited by

  1. Clinicopathological significance of Polo-like kinase 1 (PLK1) expression in human malignant glioma vol.114, pp.5, 2012, https://doi.org/10.1016/j.acthis.2011.09.004
  2. High expression of polo-like kinase 1 is associated with the metastasis and recurrence in urothelial carcinoma of bladder vol.31, pp.7, 2013, https://doi.org/10.1016/j.urolonc.2011.11.028